Webster Brian Daniel sold $1.3M of KMTS

Webster Brian Daniel (See Remarks) sold 51,900 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $24.52 ($24.47–$25.98, $1.27M total) across 3 trades on 2026-08-04.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Aug 6, 2026, 10:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but there is no new operational or financial information to reprice the business.

02

Market read

A disclosed insider sale can move short-term sentiment, but without any accompanying fundamental catalyst, expected impact is modest.

03

What to watch

The article does not state whether the insider’s remaining holdings are subject to other arrangements, nor does it provide context on prior sale frequency or total compensation-driven selling.

Relevance 6/10Novelty 3/10Timing: Filed on 2026-08-06 for sales executed 2026-08-04.

Background

The article is a SEC Form 4 insider transaction disclosure for Kestra Medical Technologies, reporting an open-market sale by an officer/director.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Webster Brian Daniel, an officer/director of Kestra Medical Technologies, sold about 51,900 shares in open-market trades totaling $1.27M.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no earnings, guidance, deal, or regulatory catalyst, and insider sales are often non-informational.

Market effects

No sector-level signal; this is company-specific insider activity without accompanying operational news.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan does not necessarily imply negative information; insiders may sell for diversification, taxes, or planned liquidity needs.

Key entities

  • Kestra Medical Technologies, Ltd.

    KMTS, the company whose insider transaction is disclosed on Form 4.

  • Webster Brian Daniel

    Officer and director who sold 51,900 shares in open-market trades totaling $1,272,587.76.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.